

Recombinant Benzonase Nuclease GMP (BenzoNuclease GMP)

PrimeGene Technical Data Sheet

Catalog Number: GMP-4A1-04
Source: Escherichia coli.

Molecular Weight: Approximately 26.8 kDa, a single non-glycosylated polypeptide chain containing 245 amino acids.

Quantity: 50KU/500KU

Purity: > 99 % by SDS-PAGE.

Biological Activity: Test by degradation of Salmon Sperm DNA, corresponding to a specific activity of $> 1.1 \times 10^6$ U/mg.

Physical Appearance: Sterile liquid.

Formulation: 50mM Tris pH8.0, 30mM NaCl, 2mM MgSO₄, 2mM DTT and 50 % glycerol. Endotoxin: Less than 0.25 EU/KU of BenzoNuclease GMP as determined by LAL method.

Sterility: Negative.

Mycoplasma: Negative when tested by RD-RCA.

Host Cell Protein: Less than 0.05% when tested by ELISA.

Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 A minimum of 12 months when stored at ≤ -20 °C as supplied. Refer to lot specific COA for the Use by Date.

3 months, -20°C under sterile conditions after opening.

Usage: This material is offered by Shanghai PrimeGene Bio-Tech for research, laboratory or further

evaluation purposes. NOT FOR HUMAN USE.

Quality statement: The manufacture and testing of this product is in compliance with ICH Q7a guidelines.

Recombinant BenzoNuclease

Recombinant BenzoNuclease is a modified recombinant Benzonase nuclease fragment. Benzonase nuclease can degrade all forms of DNA and RNA (including single strand, double strand, linear and circular) without protein cleavage activity, and has high specificity in a wide range of conditions. BenzoNuclease can completely digest nucleic acid into 5 '- monophosphate oligonucleotide with 3-5 base length (below the hybridization limit), which is most suitable for removing nucleic acid from protein. The ability of Benzonase nuclease to rapidly hydrolyze nucleic acid makes it the best choice to reduce viscosity to reduce processing time and increase protein production, which can be used to improve protein purification efficiency and function research, and can effectively prevent the aggregation of human peripheral blood mononuclear cells (PBMC) in cell therapy and vaccine research.

Shanghai PrimeGene Bio-Tech Co., Ltd.

Website: www.primegene.com
Email: info.pg@bio-techne.com
Email: info.pg@bio-techne.com
Fax: +86 21 61077348

Rev. 09/26/2022 V.1